Search

Author/Creator Yin, Philip D.

1. A phase 3, open‐label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. Issue 11 (November 2016)

Authors:
Wei, Lai; Zhang, Mingxiang; Xu, Min; Chuang, Wan‐Long; Lu, Wei; Xie, Wen; Jia, Zhansheng; Gong, Guozhong; Li, Yueqi; Bae, Si Hyun; Yang, Yong‐Feng; Xie, Qing; Lin, Shumei; Chen, Xinyue; Niu, Junqi; Jia, Jidong; Garimella, Tushar; Torbeyns, Anne; McPhee, Fiona; Treitel, Michelle
Journal:
Journal of gastroenterology and hepatology
Issue:
Volume 31:Issue 11(2016:Nov.)
Page Start:
1860
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Short‐duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study). (2nd February 2017)

Authors:
Sulkowski, Mark S.; Flamm, Steve; Kayali, Zeid; Lawitz, Eric J.; Kwo, Paul; McPhee, Fiona; Torbeyns, Anne; Hughes, Eric A.; Swenson, Eugene S.; Yin, Philip D.; Linaberry, Misti
Journal:
Liver international
Issue:
Volume 37:Number 6(2017)
Page Start:
836
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗